However, in ER+ breast cancers high CD8+ T cell levels before any treatment are either not predictive of cancer outcome (Dushyanthen et al. 2015) or linked to an unfavorable outcome (Sobral-Leite et al. 2019). This evidence concerns the gene CD8A and cancer.